#### **PHG Needs Assessment Calculator**

Fiji

## **Congenital Heart Disease**

Welcome to the PHG Health Needs Assessment Calculator for Congenital Heart Disease. The contents of this file are listed below.

Full name of the sheet	Short name
Country demographic, maternal health and socioeconomic indicators	Demography
Country health service data	HealthServices
CHD Epidemiology 1.1: Country epidemiology	CHD-E1.1
CHD Epidemiology 1.2: International comparison	CHD-E1.2
CHD Epidemiology 2.1: Data on affected pregnancies: Research studies	CHD-E2.1
CHD Epidemiology 2.2: Data on affected pregnancies: Surveillance	CHD-E2.2
CHD Epidemiology 2.3: Data on affected pregnancies: Other sources	CHD-E2.3
CHD Epidemiology 2.4: Summary of affected pregnancies	CHD-E2.4
CHD Epidemiology 2.5: Sub-population variation in affected pregnancies	CHD-E2.5
CHD Epidemiology 3.1: Mortality data: Research studies	CHD-E3.1
CHD Epidemiology 3.2: Mortality data: Vital registration data	CHD-E3.2
CHD Epidemiology 3.3: Mortality data: Other sources	CHD-E3.3
CHD Epidemiology 3.4: Summary mortality estimates	CHD-E3.4
CHD Epidemiology 3.5: Sub-population variation in mortality	CHD-E3.5
CHD Epidemiology 4.1: Population prevalence: Research studies	CHD-E4.1
CHD Epidemiology 4.2: Population prevalence: Other sources	CHD-E4.2
CHD Epidemiology 4.3: Summary of population prevalence	CHD-E4.3
CHD Epidemiology 4.4: Sub-population prevalence variation	CHD-E4.4
CHD Interventions 1: Effect of folic acid fortification	CHD-Interv1
CHD Interventions 2: Effect of folic acid supplementation	CHD-Interv2
CHD Interventions 3: Effects of prenatal screening and pregnancy management	CHD-Interv3
CHD Needs Assessment Calculator 1: Quantitative baseline	CHD-NA1
CHD Needs Assessment Calculator 3: Quantitative assessment of interventions	CHD-NA3

(There is no sheet CHD-NA2.)

Note: The Calculator sheets already contain modelled estimates from the PHGDB; note that these estimates do not include CHD associated with chromosomal disorders (e.g. Down's syndrome) and other non-cardiac malformations.

Fiji

**Shared Data** 

Demographic, maternal health and socio-economic indicators

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Demography information from that Calculator into here. The information should be the same.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Number of persons by age-group and sex		Estimates		Yo	our estimat	es	Cho	sen estim	ates
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4 years	42835	39883	82718			0			0
5-9 years	40441	37578	78019			0			0
10-14 years	42369	40015	82384			0			0
15-19 years	40818	38700	79518			0			0
20-24 years	41325	39027	80352			0			0
25-29 years	37390	36097	73487			0			0
30-34 years	32825	30710	63535			0			0
35-39 years	28778	27774	56552			0			0
40-44 years	28598	27676	56274			0			0
45-49 years	25835	24487	50322			0			0
50-54 years	20215	19794	40009			0			0
55-59 years	15735	15426	31161			0			0
60-64 years	11956	12164	24120			0			0
65+ years	23298	27424	50722			0			0
Total	0	0	849173	0	0	0	0	0	0
Female population aged 15-44 years		0			-			-	
Data year		2007 report	ed in 2007						
Source, Year			UN 2011						

Ethnicity. Please enter data for the main ethnic groups if you are working with a population that is different from that of the country.

Ethnic group	Number	% population

Fertility and mortality	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Crude birth rate: live births (LB) / year / 1000 population	21	Unicef, 2007				
Still birth rate (SB): Still births (SB) / year / 1000 total births	13	WHO, 2009				
Total births in 1000s (LB+SB) per year	18	Unicef, 2007				
Infant mortality rate: infant deaths / 1000 LB / year	15	UNICEF				
Under-5 mortality rate: U5 deaths / 1000 LB / year	17	( <b>海Q1</b> 付度F2010				
Percentage births in women >35 years		(2011), 2010				
Life expectancy at birth (yrs)	69	WHO, 2009				
% of marriages consanguineous						

	Estimate	Source, Year	Your	Source,	Chosen	Source,
Maternal health			estimate	Year	estimate	Year
Prenatal visits – at least 1 visit (%)	100	WHO, 2004				
Prenatal visits – at least 4 visits (%)						
Births attended by skilled health personnel (%)	98.5	WHO, 2007				
Contraception prevalence rate (%)						
Unmet need for family planning (%)						
Total fertility rate	2.7	WHO, 2009				
% home births						
% births at health care services						
	Estimate	Source, Year	Your	Source,	Chosen	Source,
Newborn health			estimate	Year	estimate	Year
Number of neonatal examinations by SBA / trained staff						
% neonatal examinations by SBA/ trained staff						

Socio-economic indicators	Estimate	Source, Year	Your estimate	,	Source, Year
Gross national income per capita (PPP int. \$)	4320	WHO, 2008			
% population living on < US\$1 per day					
Birth registration coverage (%)	>90	WHO, 2007			
Death registration coverage (%)	90-100	WHO, 2000			

LB = live births

PPP = purchasing power parity SBA = skilled birth attendant

Fiji Shared Data Health Services Data

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Health Services information from that Calculator into here. The information should be the same.

This section provides health-service-related information for your country.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Health Expenditure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Per capita total expenditure on health (PPP int. \$)	165	WHO, 2009				
Total expenditure on health as percentage of GDP	3.6	WHO, 2009				
Per capita government expenditure on health (PPP int. \$)	121	WHO, 2009				
External resources for health as percentage of total expenditure on health	3.3	WHO, 2009				
General government expenditure on health as percentage of total expenditure on health	73.6	WHO, 2009				
Out-of-pocket expenditure as percentage of private expenditure on health	61.2	WHO, 2009				
Private expenditure on health as percentage of total expenditure on health	26.4	WHO, 2009				
General government expenditure on health as percentage of total government expenditure	9.3	WHO, 2009				

		Source,	Your	Source,	Chosen	Source,
Health Workforce	Estimate	Year	estimate	Year	estimate	Year
Number of nursing and midwifery personnel	1660	WHO, 2003				
Nursing and midwifery personnel density (per 10,000 population)	19.8	WHO, 2003				
Number of physicians	380	WHO, 2003				
Physician density (per 10,000 population)	4.529	WHO, 2003				
Number of obstetricians						
Number of paediatricians						
Number of paediatric surgeons						
Number of paediatric cardiac surgeons						
Number of paediatric neurosurgeons						
Number of clinical geneticists						
Number of genetic counsellors						
Number of community health workers						
Number of skilled birth attendants (SBA)						
Density of SBA						
Number of lab staff providing cytogenetic testing						
Number of lab staff providing molecular genetics						

Number of lab staff providing biochemical tests for genetics			
Number of skilled health attendants			

Infrastructure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Number of maternity units						
Number of services providing specialised care for people with CD						
Number of family planning services						
Number of preconception services						
Number of services providing prenatal care						
Number of services providing newborn care						
Number of facilities providing genetic services						
Number of laboratories providing cytogenetics						
Number of laboratories providing molecular genetics						
Number of laboratories providing biochemical tests for genetics						
Number of facillities for safe terminations of pregnancies for fetal defects						

PPP = purchasing power parity GDP = gross domestic product

SBA = skilled birth attendant

CD = congenital disorders

Fiji Congenital Heart Disease CHD Epidemiology 1.1: Country epidemiology

Epidemiological indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of estimate						
Prevalence at birth and by age-group (/	1000)					
Live birth prevalence (LB)			5.10			
Stillbirth prevalence (SB)			0.05			
Total birth prevalence (LB+SB)			5.15			
All age groups			2.14			
<1 year old			3.03			
1-4 year olds			3.03			
5-14 year olds			3.19			
15-44 year olds			2.14			
45+ year olds			0.04			
Number of cases by age group	<u> </u>		·		·	
Annual live births			97			
All age groups			1,803			
<1 year olds			62			
1-4 year olds			245			
5-14 year olds			623			
15-44 year olds			868			
45+ year olds			6			
No. of cases by level of impairment						
No or minor disability			670			
Moderate disability*			1,133			
Severe disability*						
Mortality and morbidity						
Mean life expectancy (yrs)			37.1			
No. deaths < 1yr			35			
No. deaths 1-4 yrs			2			
No. deaths < 5 yrs			37			
Infant mortality / 1000 LB			1.84			
Under-5 mortality / 1000 LB			1.92			
Years of life lost						

LB = live births; SB = stillbirths \* Moderate = compensated cardiac problems, premature death preceded by average 1 year, and/or exertional disability. Severe = lifelong exertional disability

Fiji Congenital Heart Disease CHD: Epidemiology 1.2: International comparison

	Your chosen		Comparison	
Epidemiological indicator	estimates	Country	Region	World
Prevalence at birth and by age-group (/1000 p	eople)		(Oceania)	
Live birth prevalence (LB)		5.10	5.10	5.08
Stillbirth prevalence (SB)		0.05	0.05	0.05
Total birth prevalence (LB+SB)		5.15	5.15	5.13
All age groups		2.14		
<1 year olds		3.03		
1-4 year olds		3.03		
5-14 year olds		3.19		
15-44 year olds		2.14		
45+ year olds		0.04		
Number of cases by age-group				
Annual live births		97	1,178	674,738
All age groups		1,803	9,960	7,859,530
<1 year olds		62	634	278,694
1-4 year olds		245	1,885	1,090,174
5-14 year olds		623	3,483	2,543,275
15-44 year olds		868	3,934	3,868,752
45+ year olds		6	23	78,635
No. cases by level of impairment				
No or minor disability		670	1,149	2,153,904
Moderate disability*		1,133	8,386	5,705,201
Severe disability*				
Mortality and morbidity				
Mean life expectancy (yrs)		37.1		
No. deaths < 1yr		35	954	396,454
No. deaths 1-4 yrs		2	27	12,002
No. deaths < 5 yrs		37	981	408,457
Infant mortality / 1000 LB		1.84	4.13	2.99
Under-5 mortality / 1000 LB		1.92	4.25	3.08
Years of life lost				

LB = live births; SB = stillbirths \* Moderate = compensated cardiac problems, premature death preceded by average 1 year, and/or exertional disability. Severe = lifelong exertional disability

Fiji

# **Congenital Heart Disease**

CHD Epidemiology 2.1: Data on affected pregnancies: Research studies

Study author, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies listed above (or in section CHD-E2.1 of the Tool), enter the best estimates for the prevalence of affected births, still births and terminations in the country, and a range of values to reflect uncertainty or within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	LB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			
Estimates for the total country/territory Best estimate	Number of affected stillbirths	SB prevalence / 1000 TB	Comments
Lower estimate			
Higher estimate			
Estimates for the total country/territory	Number of terminations of pregnancy due to condition	ToP / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

## Fiji

## **Congenital Heart Disease**

CHD Epidemiology 2.2: Data on affected pregnancies: Surveillance

Based on surveillance data, enter the best estimates for the prevalence of the condition in live births, stillbirths and pregnancy terminations in the country. Give a range of values to reflect uncertainty and within-country variation, and use comments for information on data quality, uncertainty and representativeness.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	Birth prevalence / 1000	Comments
Best estimate			
Lower estimate			
Higher estimate			

	Number of affected stillbirths	Stillbirth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

	Number of ToP due to condition	ToP / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

Fiji Congenital Heart Disease CHD Epidemiology 2.3: Data on affected pregnancies: Other sources

	Source 1:	Source 2:	Notes
Enter year and source of data – use last year with information available.			
Basic Numbers			
Number of affected live births / year, from data source			
Total number of live births / year, from data source			
Number of affected still births / year, from data source			
Total number of stillbirths / year, from data source			
Number of ToP for affected fetus / year from data source			
Total number of affected births / year (live and still)		0	
Total number of births / year, from data source		0	
Total number of ToP / year, from data source			
Total number of women aged 15-44			
Live birth prevalence: recorded and estimated			
Recorded live birth prevalence (affected recorded live births / 1000 recorded total births)	#DIV/0	)! #DIV/0!	
Estimated completeness of recording: what proportion of true affected live births in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded live births (number of recorded live births / total live births in country or territory)			Range: 0 to 1
Estimated live birth prevalence (recorded prevalence / completeness)	#DIV/0	)! #DIV/0!	
Estimated true number of affected live births in data source (number of recorded affected live births / completeness)	#DIV/0	#DIV/0!	
Estimated number of affected live births in total population (number of affected live births from data source / (coverage x completeness))	#DIV/0	#DIV/0!	
Stillbirth prevalence: recorded and estimated			
Recorded stillbirth prevalence (affected recorded still births / 1000 recorded total births)	#DIV/0	)! #DIV/0!	
Estimated completeness of recording: what proportion of true affected stillbirths in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded stillbirths (number of recorded still births / total still births in country or territory)			Range: 0 to 1
Estimated stillbirth prevalence (recorded prevalence / completeness)	#DIV/0	#DIV/0!	
Estimated true number of affected stillbirths in data source (number of recorded affected still births / completeness)	#DIV/0	#DIV/0!	
Estimated number of affected stillbirths in total population (number of affected still births from data source / (coverage x completeness))	#DIV/0	#DIV/0!	

ToP prevalence: recorded and estimated			
Recorded ToP prevalence (ToP in affected fetuses / 1000 women aged 15-44)	#DIV/0!	#DIV/0!	
Estimated completeness of recording: what proportion of true affected pregnancy terminations in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded ToP (number of recorded ToP / total ToP in country or territory)			Range: 0 to 1
Estimated ToP prevalence (recorded prevalence / estimated completeness)	#DIV/0!	#DIV/0!	
Estimated true number of ToP in data source (number of recorded ToP / completeness)	#DIV/0!	#DIV/0!	
Estimated number of ToP in total population (number of ToP from data source / (coverage x completeness))	#DIV/0!	#DIV/0!	

**Based on the sources above**, enter the best prevalence estimates for your population, and a range of values to reflect uncertainty of estimates and within country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the whole country/territory	Number of affected live births	LB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of affected still births	SB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of ToP due to condition	ToP /1000 TB
Best estimate		
Lower estimate		
Higher estimate		

Fiji Congenital Heart Disease CHD Epidemiology 2.4: Summary of affected pregnancies

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Number of annual affected live births			97			
Annual birth prevalence / 1000 TB			5.10			
Number of annual affected still births			1			
Stillbirth prevalence / 1000 TB/year			0.05			
Number of <b>terminations of pregnancy</b> in affected fetuses /year			0			
Affected ToP / 1000 TB			0.00			

If there are specific sub-types of condition, you can repeat this exercise below. However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

## Fiji

## **Congenital Heart Disease**

# CHD Epidemiology 2.5: Sub-population variation in affected pregnancies

If the birth prevalence rates vary by population sub-group (e.g. geographically or by another factor), indicate any population groups with different prevalence estimates from the whole population and describe reasons for variation. If a group is substantially different from the general population, you may wish to conduct a needs assessment for that group alone.

Population sub- group	Number of affected live births	LB prevalence / 1000 TB	Reason for variation

Population sub- group	Number of affected stillbirths	SB prevalence / 1000 TB	Reason for variation

•	Number of ToP in affected pregnancies	ToP prevalence / 1000 TB	Reason for variation

Fiji

# **Congenital Heart Disease**

CHD Epidemiology 3.1: Mortality data: Research studies

Source, year, site	Sample size	Age group	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for the specific mortality by age-group e.g. infant, under-5s, etc., as appropriate, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Mortality estimates	Number of deaths	Ratio (deaths / 1000 LB)	Comments
Neonatal group (<28 days)			
Best estimate			
Lower estimate			
Higher estimate			
Infant group (<1 year)			
Best estimate			
Lower estimate			
Higher estimate			
Under-5 group (<5 years)			
Best estimate			
Lower estimate			
Higher estimate			
Other age group:			
Best estimate			
Lower estimate			
Higher estimate			

LB = live births

Fiji
Congenital Heart Disease
CHD Epidemiology 3.2: Mortality data: Vital registration data

Fill in the blank cells based on your vital registration data.	
Enter year and source of data	
Registered data	
Total registered live births	
Registered condition-specific neonatal deaths (first 28 days of life)	
Registered condition-specific infant deaths (first year of life)	
Registered condition-specific under-5 deaths (first 5 years of life)	
Registered condition-specific neonatal mortality ratio	#DIV/0!
(condition-specific neonatal deaths / 1000 live births in the same year)	
Registered condition-specific infant mortality (condition-specific infant deaths / 1000 live births in the same year)	#DIV/0!
Registered condition-specific under-5 mortality (condition-specific under-5 deaths / 1000 live births in the same	#DIV/0!
year)	

Adjustment for under-ascertainment of cause of death and sub-registration of deaths: Enter estimates in the highlighted cells. It is not always possible to adjust the estimates, in which case you may give the value '1', accepting that the estimates in these cases will usually be biased towards low values. (Or you may move to the next section.) It is assumed that under-ascertainment is stable across age-groups; if ascertainment varies by age-group, you could use separate estimates for each age group.

Estimated completeness of recording: what proportion of deaths in affected persons were registered as such?		Range: 0 to 1
Population coverage: what proportion of the total country/territory population is covered by the vital registration?		Range: 0 to 1
Death ascertainment (population coverage x completeness)	0	
Estimated values for the total country/ territory population		
Estimated number of live births in total population	#DIV/0!	
Estimated number of neonatal deaths in total population	#DIV/0!	
(number of deaths registered in neonatal period / ascertainment)		
Estimated number of infant deaths in total population	#DIV/0!	
(number of deaths registered in first year of life / ascertainment)		
Estimated number of under-5 deaths in total population	#DIV/0!	
(number of deaths registered in under-5s / ascertainment)		
Estimated neonatal mortality ratio (estimated neonatal deaths / 1000 live births)	#DIV/0!	
Estimated infant mortality ratio (estimated infant deaths / 1000 live births)	#DIV/0!	
Estimated under-5 mortality ratio (estimated under-5 deaths / 1000 live births)	#DIV/0!	

Fiji

# **Congenital Heart Disease**

CHD Epidemiology 3.3: Mortality data: Other sources

Source,	year, site	Sample size	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Neonatal mortal	ity	Infant mortality		Under-5 mortality	
Estimates for the total country/territory	Value	Ratio/1000 LB	Value	Ratio/1000 LB	Value	Ratio/1000 LB
Best estimate						
Lower estimate						
Higher estimate						

Fiji Congenital Heart Disease CHD Epidemiology 3.4: Summary mortality estimates

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of data collection						
Number of annual deaths in affected persons			76			
Number of annual live births (in 1000s)			19			
Number of annual affected neonatal deaths			19			
Number of affected neonatal deaths / 1000 LB			1.02			
Number of annual affected infant deaths			35			
Number of affected infant deaths / 1000 LB			1.84			
Number of annual affected under-5 deaths			37			$\neg$
Number of affected under-5 deaths / 1000 LB			1.92			
Mean life expectancy at birth in affected people			37.1			
Other indicators (e.g. survival following surgical procedure, etc)						

Fiji Congenital Heart Disease CHD Epidemiology 3.5: Sub-population variation in mortality

Age group: neonatal Population sub-group	Number of deaths in affected persons	Cause-specific, group-specific neonatal mortality ratio / 1000 LB	Reason for variation

Age group: infant	Number of deaths in	Cause-specific, group-specific infant	Reason for variation
Population sub-group	affected persons	mortality ratio / 1000 LB	

Age group: under 5	Number of deaths in	Cause-specific, group-specific	Reason for variation	
Population sub-group	affected persons	under-5 mortality ratio / 1000 LB		

Age group:	Number of deaths in	Cause-specific, group-specific	Reason for variation	
Population sub-group	affected persons	mortality ratio / 1000 population		

Fiji

# **Congenital Heart Disease**

CHD Epidemiology 4.1: Population prevalence: Research studies

Study, year, site	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for population prevalence, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

Fiji

# **Congenital Heart Disease**

CHD Epidemiology 4.2: Population prevalence: Other sources

Source, year, site	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

Fiji Congenital Heart Disease CHD Epidemiology 4.3: Summary of population prevalence

Source of estimates	Estimated total population number of affected persons	Range	Estimated total population prevalence / 1000 persons	Range
1				
2				
3				
4				
5				
PHGDB				
Chosen estimates				

Fiji Congenital Heart Disease CHD Epidemiology 4.4: Sub-population prevalence variation

Population sub-group	Number of affected people	 Population prevalence per 1000 people	Reason for variation
		#DIV/0!	

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

Formula in column D: Number of affected people/ (Total number of people in population subgroup/1000)

## Fiji

#### **Congenital Heart Disease**

#### CHD Interventions 1: Effect of folic acid fortification

This sheet allows you to estimate the potential reduction in CHD prevalence through fortification of food with folic acid. Please start by entering values reflecting your current situation. If you have no fortification programme, enter 0 for coverage. Below, you may adjust dosage and coverage levels to demonstrate the effects of different intervention scenarios.

Current situation	Notes
Present estimated CHD prevalence per 1000 TB	
Present dosage (ppm)	Range: 1.5 to 3
Present coverage of fortification	Range: 0 to 1
Baseline CHD prevalence per 1000 TB, with no folic acid fortification*1	

Potential scenarios, based on your present situation	
Vary dosage (ppm)	Range: 1.5 to 3
Vary proportional population coverage Estimated reduction in CHDs through folic acid fortification, per 1000	Range: 0 to 1
Estimated reduction in CHDs through folic acid fortification, per 1000 TB <sup>2</sup>	0.000 Do not delete this value!
Resulting prevalence of CHDs after folic acid fortification, per 1000 TB <sup>3</sup>	0.000 Do not delete this value!

ppm = parts per million

TB = total births (live births + still births)

The regression formula underlying the effect on neural tube defects is given in the NTD Calculator in this Toolkit.

<sup>\*</sup> The effect of folic acid on CHD is assumed to be 25% of the effect on neural tube defects.

<sup>\*\*</sup> Not considering the effects of other interventions on prevalence.

<sup>&</sup>lt;sup>1</sup>(Present estimated prevalence-(1.07\*coverage\*0.25)+(0.15\*ppm\*coverage\*0.25))/(1-0.88\*coverage\*0.25)))

 $<sup>^2((0.25*(</sup>Baseline\ CHD-(1.07*coverage+0.12*baseline\ CHD*coverage-0.15*dosage*coverage+baseline-baseline*coverage))))$ 

<sup>&</sup>lt;sup>3</sup>Baseline CHD prevalence – estimated reduction in CHD after fortification

#### Fiji

## **Congenital Heart Disease**

## CHD Interventions 2: Effect of folic acid supplementation

This sheet allows you to estimate the potential reduction in CHD incidence through folic acid supplementation for pregnant women. Please enter a value for population coverage of folic acid supplementation, to determine its potential effect.

Effect of supplementation (with no fortification)		Notes
Baseline prevalence with no folic acid intervention (per 1000 TB)		This can be taken from the appropriate cell in the previous sheet.
Maximum proportional reduction (assuming 100%		
coverage)	0.18	This value is fixed at 0.18
Population supplementation coverage		Range: 0 to 1
Actual proportional reduction	0	Maximum proportional reduction x Coverage
Actual prevalence reduction (per 1000 TB)	0.000	Baseline prevalence x Actual proportional reduction

New prevalence		Baseline prevalence -((Maximum prop. Reduction x Population supplementation coverage) x Baseline prevalence))
% prevalence reduction	#DIV/0!	1-(New prevalence/Baseline prevalence)
Absolute prevalence reduction (per 1000 TB)	0.000	Baseline prevalence -New prevalence

Now you can see below the potential combined effect of folate fortification and supplementation:

Additional effect of supplementation, given	0.1 This value can be changed.
fortification	

	New prevalence	
After fortification		This can be taken from the appropriate cell above
After supplementation	0.000	Same as new prevalence
		Prevalence after fortification-(Additional effect of
After fortification and supplementation		supplementation*prevalence after supplementation)

TB = total births (live births + still births)

CHD = congenital heart disease

<sup>1</sup>New Prevalence after fortification-(Additional effect of supplementation x Final prev. following supplemen.)

<sup>2</sup>If New prevalence after fortification < minimum prevalence then use (Baseline prev – min prevalne)/baseline prevalance)

Otherwise use: (Baseline prevalence – new prevalence after fortification and supplementation)/baseline prevalence

Fiji
Congenital Heart Disease
CHD Interventions 3: Effect of prenatal screening and pregnancy management

Baseline prevalence: fetuses affected by CHD, per 1000 TB		See previous sheet. Use baseline prevalence either before or after folic acid fortification and supplementation.
Variables		
Coverage of prenatal screening		Range: 0 to 1
Proportion of diagnosed pregnancies receiving treatment*		Range: 0 to 1
Effectiveness of treatment		Range: 0 to 1
Results		
Proportional reduction of uncontrolled cases of CHD through PNS and treatment <sup>1</sup>	0%	
Prevalence of uncontrolled CHD after PNS and treatment, per 1000 total births <sup>2</sup>	0.000	
Final prevalence: affected live births after PNS & treatment, per 1000 total births <sup>3</sup>	0.000	

PNS = prenatal screening
TB = total births (live births + still births)
CHD = congenital heart disease

<sup>\*</sup>Treatment in this case refers to diagnosis and appropriate management of pregnancy

<sup>&</sup>lt;sup>1</sup>Coverage of screening X Proportion of diagnosed pregnancies receiving treatment X Effectiveness of treatment

<sup>&</sup>lt;sup>2</sup>Proportional reduction of uncontrolled cases x Baseline prevalence

<sup>&</sup>lt;sup>3</sup>Baseline prevalence – prevalence of uncontrolled CHD

#### CHD Interventions: Effect of prenatal screening and pregnancy termination

Assumption: prenatal services are equally used for cases which would lead to still births and live births.

This could overestimate the impact of ToP if in fact ToP is more likely for severe cases that would result in stillbirth.

Conversely, the impact of ToP could be underestimated if screening is only available to high-income women at lower risk.

100% specificity of prenatal diagnosis assumed.

Baseline prevalence, per 1000 TB (LB + SB)		See previous two sheets. Use baseline either before or after folic acid interventions.
Variables		
Coverage of prenatal screening		Range: 0 to 1
Proportion of screen-positive cases receiving diagnosis		Range: 0 to 1
Proportion of diagnosed cases ending in pregnancy termination		Range: 0 to 1
Results		
% prevalence reduction due to PND & pregnancy termination <sup>1</sup>	0%	
Prevalence reduction due to PND & pregnancy termination, per 1000 TB <sup>2</sup>	0.000	
Final birth prevalence of CHDs after PND & pregnancy termination, per 1000 TB <sup>3</sup>	0.000	

PNS = prenatal screening

ToP = termination of pregnancy

TB = total births (live births + still births)

<sup>&</sup>lt;sup>1</sup>Coverage of screening X Proportion of screen-positive cases receiving diagnosis x Proportion of cases ending in pregnancy termination

<sup>&</sup>lt;sup>2</sup>% prevalence reduction due to PND and termination x Baseline prevalence

<sup>&</sup>lt;sup>3</sup>Baseline prevalence – Prevalence reduction due to PND & termination

Fiji Congenital Heart Disease

**CHD Needs Assessment Calculator 1: Quantitative baseline** 

Table CHD-NA1a Burden of Neural Tube Defects in pregnancy, at birth and at population level

	Chosen estimates			Notes
Indicator	Number (n)	l .	Range of prevalence (/1000 TB)	
Annual affected live births (LB)	0	0	0	Drawn from sheet E2.4
Annual affected stillbirths (SB)	0	0	0	Drawn from sheet E2.4
Annual affected births (LB+SB)	0	0		Drawn from sheet E2.4
Annual affected persons (all age	0	0	0	Drawn from sheet E1.1
groups)				

Table CHD-NA1b Neural Tube Defects mortality indicators

	Chosen estimates			Notes
Indicator	Number (n)	l .	Range of prevalence (/1000 TB)	
Annual overall mortality	0			Drawn from sheet E3.4
Annual neonatal mortality	0	0	0	Drawn from sheet E3.4
Annual infant mortality	0	0	0	Drawn from sheet E3.4
Annual under-5 mortality	0	0	0	Drawn from sheet E3.4
Mean life expectancy at birth among affected people	0		0	Drawn from sheet E3.4

TB = total births (live births + stillbirths)

# Fiji Congenital Heart Disease

# CHD Needs Assessment Calculator 3: Quantitative assessment of interventions

Table CHD-NA3a	•	Estimated prevalence in the absence of interventions for Neural Tube Defects			
Indicator	Number (n)	Number (n) Prevalence (n/1000)			
Potential live births					
Potential still births					

Table CHD-NA3b	<b>Current situation in relat</b>	ion to interventions before	e birth
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 TB
Effect of family planning, education			
Effect of multivitamin and folic acid supplementation			
Control of teratogens			
Management of diseases in pregnancy, e.g diabetes			
Rubella prevention			
Effect of prenatal diagnosis			
Overall effect			

Table CHD-NA3c	Target situation in relation to interventions before birth			
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 TB	
Effect of family planning, education				
Effect of multivitamin and folic acid supplementation				
Control of teratogens				
Management of diseases in pregnancy, e.g diabetes				
Rubella prevention				
Effect of prenatal diagnosis				
Overall effect				

PHG FOUNDATION VERSION 1.0, NOVEMBER 2011

Table CHD-NA3d	Current situation in relation to interventions after birth			
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 TB	
Effect of newborn screening				
Effect of newborn diagnosis				
Effect of echocardiography services				
Effect of primary care diagnosis				
Effect of paediatric cardiology				
Effect of paediatric cardiac surgery				
Effect of acute clinical care				
Effect of social care and support				
Effect of rehabilitation				
Overall effect				

Table CHD-NA3e	Target situation in relation to interventions after birth			
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 TB	
Effect of newborn screening				
Effect of newborn diagnosis				
Effect of echocardiography services				
Effect of primary care diagnosis				
Effect of paediatric cardiology				
Effect of paediatric cardiac surgery				
Effect of acute clinical care				
Effect of social care and support				
Effect of rehabilitation				
Overall effect				

Table CHD-NA3f	Current and desired outo	comes			
	Current situation		Target situation		
Indicator	Annual number (n)	Prevalence (n/1000)	Annual number (n)	Prevalence (n/1000)	
Estimated affected pregnancies					
Live births (LB)	0	0			
Stillbirths (SB)	0	0			
Total births (LB+SB)	0	0			
Estimated population prevalence					
All age groups					
Estimated mortality / 1000 live births					
Neonatal deaths	0	0			
Infant deaths	0	0			
Under-5 deaths	0	0			

TB = total births (live births + stillbirths)